Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENVB 
Enveric Biosciences Inc (ENVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ENVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.49% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.97M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 0.37 | 52 Weeks Range 0.62 - 8.32 | Updated Date 09/17/2025 |
52 Weeks Range 0.62 - 8.32 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.73% | Return on Equity (TTM) -261.96% |
Valuation
Trailing PE - | Forward PE 23.09 | Enterprise Value 120533 | Price to Sales(TTM) 0.08 |
Enterprise Value 120533 | Price to Sales(TTM) 0.08 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA 0.29 | Shares Outstanding 3246280 | Shares Floating 3222067 |
Shares Outstanding 3246280 | Shares Floating 3222067 | ||
Percent Insiders 6.84 | Percent Institutions 10.2 |
Upturn AI SWOT
Enveric Biosciences Inc
Company Overview
History and Background
Enveric Biosciences, Inc., founded in 2014, is a biotechnology company focused on developing novel neuroplastogenic small molecule therapeutics for the treatment of anxiety, depression, and PTSD. It initially focused on cannabinoid-based therapies before shifting its focus to psychedelic-inspired molecules.
Core Business Areas
- EVM201 Series: This segment involves the development of molecules designed to promote neuroplasticity and treat mental health disorders. The product includes psilocin prodrugs.
- Psybrary: This involves the discovery and development of novel psychedelic-inspired molecules using a drug discovery platform.
Leadership and Structure
The leadership team includes Joseph Tucker, Ph.D., CEO. The company has a board of directors that oversees strategic direction. The organizational structure is typical of a small biotech company, with research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- EVM201 Series: These are novel, patented, prodrugs of psilocin, the active metabolite of psilocybin. These are being developed for the treatment of mental health conditions. Enveric's primary competitors for EVM201 include companies developing similar psilocybin-based therapies, such as COMPASS Pathways (CMPS), and ATAI Life Sciences (ATAI). Market share data is not yet applicable, given the product is in development stages.
- Psybrary: This is their drug discovery platform which contains numerous compounds with the potential to become therapeutics. There is no market share associated with this yet. Competitors developing discovery platforms include Recursion Pharmaceuticals (RXRX).
Market Dynamics
Industry Overview
The industry is characterized by high growth potential, but also high risk due to stringent regulatory requirements and clinical trial hurdles. There's a significant unmet need for effective mental health treatments, driving innovation.
Positioning
Enveric is positioned as an innovator in the development of next-generation psychedelic-inspired therapeutics. It aims to distinguish itself through its focus on neuroplasticity and its proprietary drug discovery platform.
Total Addressable Market (TAM)
The global mental health market is expected to reach hundreds of billions of dollars in the coming years. Enveric is positioned to capture a share of this market through the development of novel therapeutics. The precise TAM varies based on the specific indications targeted by its pipeline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (neuroplastogens)
- Proprietary drug discovery platform
- Strong IP portfolio
Weaknesses
- Early stage development (high risk)
- Limited financial resources
- Dependence on regulatory approvals
Opportunities
- Growing market for mental health treatments
- Potential for partnerships and collaborations
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
- GHRS
Competitive Landscape
Enveric competes with other biotech companies developing psychedelic-inspired therapeutics. Its competitive advantage lies in its unique approach to neuroplasticity and its proprietary drug discovery platform. However, competitors may have greater financial resources and more advanced clinical programs. Market share is currently negligible for all competitors since all are in early stages.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical research and development progress.
Future Projections: Future growth is dependent on successful clinical trials and potential commercialization of its drug candidates. Analyst estimates vary widely, reflecting the uncertainty inherent in drug development.
Recent Initiatives: Recent initiatives include advancing its EVM201 series into clinical trials and expanding its Psybrary drug discovery platform.
Summary
Enveric Biosciences is a high-risk, high-reward biotech company focusing on innovative mental health treatments. The company's strengths lie in its novel approach and drug discovery platform, but it faces challenges related to funding, regulatory approvals, and clinical trial outcomes. Positive clinical data and strategic partnerships are crucial for its future success. Investors should exercise caution due to the inherent uncertainty in early-stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enveric Biosciences Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-06-24 | CEO & Director Dr. Joseph Edward Tucker Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.enveric.com |
Full time employees 5 | Website https://www.enveric.com | ||
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.